| Name | HUTCHMED (China) Limited |
|---|---|
| Epic | HCM |
| Isin | KYG4672N1198 |
| Index | AIM50 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 220.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £1,918.73 | Debt ratio | n/a |
| Shares in issue | 872.15 | Debt-to-equity ratio | n/a |
| P/E ratio | 78.8 | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -4.43 |
| Dividend cover | n/a | EPS growth | -67 |
| Earning per share | 4 | 52-week high / low | 189.00p / 290.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | HUTCHMED (China) Limited |
|---|---|
| Address | PO Box 309, Ugland House, George Town, Grand Cayman, Cayman Islands, KY1-1104 |
| Telephone | +1 345 949 8066 |
| Website | http://www.hutch-med.com |
| Director | Position |
|---|---|
| Dr Weiguo Su | CEO |
| Mr Dan Eldar | Chairman |
| Dr Renu Bhatia | Non-Executive Director |
| Ms Ling Yang | Non-Executive Director |
| Professor Shu Kam Tony | Senior Independent Director |
| Prof. Tan Shao Weng | Independent Non-Executive Director |
| Dr. Chaohong HU | Independent Non-Executive Director |
| Mr Wong Tak Wai | Independent Non-Executive Director |
| Ms Edith Shih | Non-Executive Director and Company Secretary |
| Mr Johnny Cheng | CFO & Executive Director |
| Assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | 82.77 | 48.41 | 73.78 |
| Total non-current assets | 207.64 | 182.93 | 189.56 |
| Inventory / work in progress | 50.4 | 50.26 | 56.69 |
| Trade and other receivables | 180.04 | 160.24 | 152.2 |
| Cash and equivalents | 153.96 | 283.59 | 313.28 |
| Other current assets and asset held for resale | 682.15 | 602.75 | n/a |
| Total of all assets | 1274.2 | 1279.77 | 1029.44 |
| Liabilities $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 376.56 | 403.03 | 353.9 |
| Long term liabilities | 125.78 | 133.36 | 38.67 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 502.34 | 536.39 | 392.58 |
| Net assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 771.85 | 743.39 | 636.87 |
| Equity $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 87.16 | 87.13 | 86.48 |
| Minority interests | 11.92 | 12.85 | 26.5 |
| Retained earnings | -833.17 | -870.87 | -971.48 |
| Share premium account | 1517.53 | 1522.45 | 1497.27 |
| Total equity | 771.85 | 743.39 | 636.87 |
| Income $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 41.49 | 18.38 | -407.69 |
| Pre-tax profit | -1.11 | 58.31 | -410.42 |